Triple targeted therapy for advanced bowel cancer improves survival

Patients with metastatic colorectal cancer who have a BRAF mutation have improved survival after treatment with three targeted therapies instead of standard chemotherapy, results from a phase III trial have shown.
Source: Clinical Pharmacist - Category: Drugs & Pharmacology Source Type: research